ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.

Hegi-Johnson, Fiona; Rudd, Stacey E; Wichmann, Christian; Akhurst, Tim; Roselt, Peter; Trinh, Jenny; John, Thomas; Devereux, Lisa; Donnelly, Paul S; Hicks, Rod; Scott, Andrew M; Steinfort, Daniel; Fox, Stephen; Blyth, Benjamin; Parakh, Sagun; Hanna, Gerard G; Callahan, Jason; Burbury, Kate; MacManus, Michael

doi:10.1136/bmjopen-2021-056708

Title

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.

Publication Date

2022-11-18

Author(s)

Hegi-Johnson, Fiona

Rudd, Stacey E

Wichmann, Christian

Akhurst, Tim

Roselt, Peter

Trinh, Jenny

John, Thomas

Devereux, Lisa

Donnelly, Paul S

Hicks, Rod

Scott, Andrew M

Steinfort, Daniel

Fox, Stephen

Blyth, Benjamin

Parakh, Sagun

Hanna, Gerard G

Callahan, Jason

Burbury, Kate

MacManus, Michael

Subject

Nuclear radiology

Radiation oncology

Respiratory tract tumours

Type of document

Journal Article

OrcId

0000-0002-4543-8802

#PLACEHOLDER_PARENT_METADATA_VALUE#

0000-0003-1003-5138

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1136/bmjopen-2021-056708

Abstract

ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if 89Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials.

Link

link

Citation

BMJ Open 2022; 12(11)

Jornal Title

BMJ Open

ISSN

2044-6055

Austin Health

Files: